A DAT scan is a nuclear medicine imaging test in which a small amount of a radioactive tracer is injected into your vein, allowed to travel to your brain, and then photographed using a specialized camera that rotates around your head. The whole visit typically takes three to five hours, though the actual time under the camera is closer to 30 to 45 minutes. Most of the waiting is just the tracer doing its job: binding to dopamine transporters deep in the brain so the camera can capture a usable picture.
What the Scan Is Actually Measuring
The radiotracer used in a DAT scan is called ioflupane, labeled with a radioactive form of iodine (iodine-123). Chemically, it is a modified version of a cocaine-like compound, engineered to latch onto dopamine transporter proteins sitting on the surface of nerve cells in a region called the striatum.1Journal of Nuclear Medicine Technology. Pitfalls and Artifacts of 123I-Ioflupane SPECT in Parkinsonian Syndromes: A Quality Improvement Teaching Tool The tracer has a strong preference for dopamine transporters over other brain receptors, with roughly ten times more affinity for dopamine transporters than for serotonin transporters.2PubMed Central. Association between body mass index (BMI) and [123I]Ioflupane (DaTSCAN) availabilities in patients with parkinsonism using single-photon emission computed tomography–computed tomography (SPECT-CT)
When those dopamine-producing nerve endings are healthy, the tracer accumulates heavily in two comma-shaped structures in the brain and lights up brightly on the scan. When the nerve endings have degenerated, as happens in Parkinson’s disease, there are fewer transporters for the tracer to bind. The resulting image looks dimmer, often losing the characteristic comma shape on one or both sides. That difference between a healthy pattern and a depleted one is the entire diagnostic value of the test.
Why Your Doctor Ordered One
DAT scans are not routine screening tools. They are ordered when a neurologist is genuinely uncertain whether someone’s symptoms are caused by a neurodegenerative process affecting dopamine or by something else entirely. The most common scenario is a patient whose tremor could be either Parkinson’s disease or essential tremor, two conditions that look similar at the bedside but arise from completely different brain pathology.3PubMed Central. Distinguishing essential tremor from Parkinson’s disease: bedside tests and laboratory evaluations In essential tremor, the dopamine system is intact and the scan looks normal. In Parkinson’s, it does not.
The scan also helps distinguish Parkinson’s disease from drug-induced parkinsonism (movement symptoms caused by certain medications), psychogenic movement disorders, and some forms of dystonia, all of which produce normal-looking scans. On the other side, conditions like dementia with Lewy bodies and the Parkinson-plus syndromes show abnormal scans, because they too involve dopamine nerve loss.4Parkinsonism & Related Disorders. What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective The scan can confirm that dopamine degeneration is present, but it cannot tell you which specific degenerative condition is responsible. If your neurologist needs to separate Parkinson’s from, say, multiple system atrophy, other tests have to fill that gap.
Preparing for the Scan
Preparation starts days before the appointment, mainly involving medications. Certain drugs block the same dopamine transporter the tracer needs to reach, and using them close to the scan date can produce a misleading result. Cocaine and amphetamines are the most dramatic offenders. Cocaine blocks roughly 60 to 77 percent of striatal dopamine transporters in a living brain, and amphetamines reduce transporter binding through a different mechanism. A recent case report showed that amphetamine use produced an abnormal-looking scan in someone who did not actually have dopamine neuron loss.5PubMed Central. A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice Current guidance recommends against performing the scan in anyone actively using these substances.
Several prescription medications also need to be paused or discussed with your neurologist beforehand. These commonly include certain antidepressants (particularly SSRIs and SNRIs at higher doses), some ADHD medications, and specific anti-nausea drugs. Your referring physician and the nuclear medicine department will give you a specific list and timeline for stopping any potentially interfering medication. Not every drug on these lists has strong evidence of interference, but the cautious approach is standard practice.
Because the tracer contains radioactive iodine, you will typically be given a thyroid-blocking agent before the injection. Potassium iodide, Lugol’s solution, or potassium perchlorate are the usual choices. The goal is to saturate your thyroid with non-radioactive iodine so it does not absorb the small amount of radioactive iodine released as the tracer breaks down. This is a precaution, not an indication that the radiation dose is dangerous. You will generally take this medication an hour or so before the injection and sometimes continue it for a day afterward.
What Happens on Scan Day
The procedure itself is straightforward, though the waiting can feel tedious. You arrive at the nuclear medicine department, confirm your medication history and any allergies, and receive the ioflupane injection through a standard IV line in your arm. The injection takes just a few seconds and is no different from a typical blood draw in terms of discomfort. The tracer is a clear liquid with essentially no side effects for most people, though mild headache or nausea has occasionally been reported.
After the injection, you wait. This is the longest part of the visit. The tracer needs about three to four hours to circulate through your blood, cross the blood-brain barrier, and accumulate on the dopamine transporters in your striatum. During this waiting period you can read, use your phone, or eat. You are not radioactive in any way that requires isolation from other people, though the department may ask you to stay in a waiting area rather than leaving the building.
When the tracer has had enough time to bind, you are taken to the imaging room and positioned on a narrow table. The camera used is a SPECT (single-photon emission computed tomography) system, which consists of one or more large detector heads that slowly rotate around your head. Your head is gently immobilized, sometimes with a headrest and straps, because even small movements can blur the images. The detector heads come close to your head but do not touch it, and the machine is quieter than an MRI scanner. There is no enclosed tunnel. The actual image acquisition takes approximately 30 to 45 minutes. You need to stay still during this time, but there is no pain, no loud banging, and no claustrophobic enclosure for most systems.
Head movement during the scan is a genuine concern for image quality. Even a slight rotation of the head can produce an artifact known as the “pinwheel sign,” which distorts the appearance of the striatum on the final images and can lead to incorrect interpretation.6Journal of Nuclear Medicine Technology. The Pinwheel Sign: Artifact from Head Rotation During SPECT Acquisition for Dopamine Transporter Imaging Technologists monitor you during the scan for this reason and may restart the acquisition if significant motion is detected.
How the Images Are Read
Once the scan data is collected, a nuclear medicine physician or a neuroradiologist interprets the images. The reading process involves two complementary approaches: a visual assessment and a numerical measurement.
The visual assessment is exactly what it sounds like. The physician looks at the reconstructed brain images and evaluates the shape and brightness of the tracer uptake in the striatum. In a healthy scan, the two striatal regions appear as bright, comma-shaped or crescent-shaped areas, sometimes described as looking like two tadpoles or quotation marks. In Parkinson’s disease, the tail of the comma (corresponding to the putamen) fades first, often on one side before the other, giving a “dot” or “egg” shape instead of a comma. With more advanced disease, both the head and tail lose signal.
The semiquantitative assessment adds numbers to the picture. Software calculates a “specific binding ratio,” essentially a comparison of how much tracer accumulated in the striatum versus a reference region of the brain where little specific binding occurs.7PubMed Central. Count-based method for specific binding ratio calculation in [I-123]FP-CIT SPECT analysis That ratio is then compared against age-matched normal values. A ratio that falls below a certain threshold supports a diagnosis of dopaminergic loss. Different software packages and different imaging centers may use slightly different methods to draw the regions and calculate the ratio, which is one reason why scans are ideally read at experienced centers using standardized protocols.8PubMed Central. Semiquantitative Analysis of Dopamine Transporter Scans in Patients With Parkinson Disease
Not every scan falls neatly into the “normal” or “abnormal” category. Some show borderline findings: a slightly reduced putamen signal, mild asymmetry between the two sides, or a preserved comma shape with lower-than-expected numerical values.9Life. Equivocal Dopamine Transporter Imaging: Integrating Visual Assessment, Quantification, and Clinical Follow-Up These equivocal scans are frustrating for patients and doctors alike. They often lead to a recommendation for clinical follow-up and sometimes a repeat scan a year or two later to see whether the pattern has progressed.
How Accurate Is a DAT Scan
When the scan is ordered for the right clinical question, its diagnostic performance is strong. A systematic review found that in patients with clinically uncertain parkinsonism, DAT SPECT had sensitivity and specificity rates of about 98 percent for detecting underlying dopamine nerve loss.10PubMed Central. The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson’s disease or clinically uncertain parkinsonism: a systematic review In studies where patients already had a confirmed clinical diagnosis of Parkinson’s disease, sensitivity reached 100 percent, though that is partly because those patients were selected for having clearly established disease.
A separate study that compared initial DAT scan images against the clinical diagnosis reached three years later found a sensitivity of 78 percent and specificity of about 97 percent for early parkinsonian syndromes.11Journal of Nuclear Medicine. Accuracy of DaTscan™ (Ioflupane I 123 Injection) in diagnosis of early parkinsonian syndromes (PS) The lower sensitivity here reflects how difficult very early disease can be to detect: some patients scanned at the earliest stages have not yet lost enough dopamine nerve terminals for the image to look clearly abnormal.
When the Scan Gets It Wrong
The most talked-about limitation involves a group of patients researchers call “SWEDD,” which stands for “scans without evidence of dopaminergic deficit.” These are people who look clinically like they have Parkinson’s disease but whose DAT scans come back normal. For years, this sparked debate about whether the scan was missing real disease or whether these patients actually had a different condition misdiagnosed as Parkinson’s.
The answer turns out to be a mix. Research tracking SWEDD patients over time found that about two-thirds eventually developed clearly abnormal scans, with reduced binding ratios falling below the normal range and worsening motor scores.12PubMed Central. Long-term follow-up study of SWEDD patients with mild parkinsonian signs This suggests many of them did have early dopamine neuron loss that the initial scan was simply too early to catch. At the same time, other SWEDD patients show a fundamentally different pattern: their dopamine levels remain stable over years, suggesting their symptoms arise from a different mechanism altogether.13NeuroImage: Clinical. Distinctive clinical and imaging trajectories in SWEDD and Parkinson’s disease patients
Age adds another wrinkle. Older patients who present with early symptoms may be more likely to have a normal-appearing scan despite having genuine dopamine degeneration. One explanation is that compensatory strategies in the brain’s dopamine system become less effective with age, meaning older patients may develop noticeable symptoms at an earlier stage of nerve loss, before enough transporter depletion has occurred for the scan to flag it.14PubMed Central. Negative DAT-SPECT in Old Onset Parkinson’s Disease: An Additional Pitfall? A normal scan in a 75-year-old with suspicious symptoms may deserve more skepticism than the same result in a 50-year-old.
How the Result Changes Your Treatment
A DAT scan is not just a confirmation exercise. The result frequently reshapes what happens next. In one retrospective study, physicians reported that the scan changed their diagnosis in about two-thirds of patients and altered clinical management in nearly 60 percent.15PubMed Central. The impact of DaTscan on the diagnosis and management of movement disorders: A retrospective study A larger, more recent eight-year review found the diagnosis was changed in roughly 37 percent of patients, while management changed in about 42 percent, with nearly two-thirds of those changes involving the start of dopaminergic medications.16PubMed Central. Dopamine transporter single photon emission computed tomography (DaT-SPECT) use in the diagnosis and clinical management of parkinsonism: an 8-year retrospective study Another study in a cohort of clinically uncertain cases found diagnosis changes in about 40 percent of patients and medication changes in 70 percent.17PubMed Central. Impact of DaTscan Imaging on Clinical Decision Making in Clinically Uncertain Parkinson’s Disease
The practical stakes are real. If the scan is normal and your symptoms are not caused by dopamine neuron loss, starting Parkinson’s medications would expose you to side effects with no benefit. If the scan is abnormal, beginning treatment earlier may improve quality of life. Beyond medication decisions, the result can also steer patients toward more appropriate monitoring, referral to movement disorder specialists, or reassurance that their condition is not neurodegenerative.
Medications and Substances That Interfere
The list of drugs that can potentially alter DAT scan results has been studied more carefully over the past decade, and the picture is more nuanced than earlier guidance suggested. The clearest offenders, as noted earlier, are cocaine and amphetamines including methamphetamine and prescription stimulants. These drugs block or reduce dopamine transporter availability so dramatically that a scan performed while they are still affecting the brain can look abnormal even in someone with a perfectly healthy dopamine system.5PubMed Central. A systematic review of the potential effects of medications and drugs of abuse on dopamine transporter imaging using [123I]I-FP-CIT SPECT in routine practice
For many other commonly used medications, including most antidepressants at standard doses, the evidence of meaningful interference is less clear-cut. SSRIs, for example, have some theoretical interaction with the tracer because of its low-level serotonin transporter binding, but clinical studies have not consistently shown that standard-dose SSRI use produces scans that look abnormal. The conservative approach, stopping antidepressants before the scan, carries its own risks, particularly for patients with depression or anxiety. Nuclear medicine teams increasingly take a case-by-case approach, weighing the likelihood of drug interference against the clinical danger of abrupt medication withdrawal.
If you are concerned about a medication on your list, bring it up with both your neurologist and the nuclear medicine department before the scan date. They can advise you on which drugs genuinely need to be paused, for how long, and which can safely continue.
What a DAT Scan Cannot Tell You
A common misconception is that a DAT scan can pinpoint exactly which neurodegenerative condition you have. It cannot. The scan tells you whether your dopamine nerve terminals are depleted, and roughly how depleted they are. It does not distinguish between Parkinson’s disease, multiple system atrophy, progressive supranuclear palsy, or corticobasal degeneration, because all of these cause dopamine neuron loss in the same brain region. Differentiating among them requires additional information: your clinical symptoms, how the disease progresses, and sometimes other imaging tests like a cardiac MIBG scan or an FDG-PET scan that evaluates brain metabolism patterns.4Parkinsonism & Related Disorders. What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective
The scan also does not measure disease severity in a way that maps neatly onto how you feel day to day. Two patients can have similar-looking scans but very different levels of motor difficulty, because symptoms depend on a whole constellation of factors beyond dopamine transporter density alone. Doctors use the scan to answer a specific binary question: is there dopaminergic degeneration or not? Grading severity or predicting how fast someone will progress is not something the scan does reliably on its own.
Radiation Exposure and Safety
The radiation dose from a DAT scan is comparable to what you would receive from a few years of natural background radiation, or roughly in the range of a standard CT scan. The tracer’s iodine-123 has a short half-life of about 13 hours, meaning half of the radioactivity disappears within that time. Within a few days, essentially all of it has been eliminated from your body through natural processes, primarily via urine. The thyroid-blocking agent you take before the injection further reduces any lingering thyroid exposure.
For pregnant or breastfeeding women, the scan is generally avoided unless the clinical need is urgent, as is standard practice with any nuclear medicine study. For everyone else, the radiation dose is considered acceptable relative to the diagnostic information the scan provides, especially in cases where the clinical picture is genuinely uncertain and the result will change management.
After the Scan
Once imaging is complete, you can go home. There are no lingering effects from the tracer, no driving restrictions, and no need for someone to accompany you unless you have mobility issues unrelated to the procedure. You can eat and drink normally. Some departments recommend drinking extra fluids and urinating frequently for the rest of the day to help clear the tracer a bit faster, though this is precautionary rather than medically necessary.
Results are typically reported to your referring neurologist within a few days, depending on the institution. The nuclear medicine physician provides a formal read that includes both the visual impression and, in most cases, semiquantitative binding ratios. Your neurologist then integrates this with your clinical history, exam findings, and any other test results to reach a working diagnosis. For patients whose results fall in the equivocal range, the next step may be watchful waiting with a follow-up scan in 12 to 24 months, since a repeat scan can reveal whether a borderline pattern has progressed into a clearly abnormal one or remained stable.
If your scan is clearly normal, it usually provides significant reassurance that your symptoms are not caused by a neurodegenerative loss of dopamine neurons. That is worth a lot, both diagnostically and emotionally. If the scan is clearly abnormal, it sets the stage for a focused treatment plan and often resolves months or years of clinical uncertainty. For the minority of scans that land somewhere in between, patience and follow-up are the appropriate response rather than alarm.